Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Mar;64(3):298–305. doi: 10.1136/jnnp.64.3.298

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

N Andreasen 1, E Vanmechelen 1, A Van de Voorde 1, P Davidsson 1, C Hesse 1, S Tarvonen 1, I Raiha 1, L Sourander 1, B Winblad 1, K Blennow 1
PMCID: PMC2170016  PMID: 9527138

Abstract

OBJECTIVES—Biochemical markers for Alzheimer's disease would be of great value, especially to help in diagnosis early in the course of the disease. A pronounced increase in CSF tau protein (CSF-tau) is found in most patients with Alzheimer's disease. However, the specificity has to be further studied, as an increase in CSF-tau has also been found in other dementias, especially in vascular dementia. As most previous CSF studies have been based on selected inpatients, it was considered of special interest to examine the diagnostic potential of CSF-tau in a community population based sample of consecutive patients with dementia. Such patient material has been examined at the Piteå River Valley Hospital in Northern Sweden since 1986, and includes all those with memory disturbances in the community. The aim was also to study if an increase in CSF-tau is found early in the disease process, and whether CSF-tau changes during the progression of disease.
METHODS—Participants: Community population based sample of 75 demented patients (43 with Alzheimer's disease, 21 with vascular dementia, and 11 with mixed Alzheimer's disease/vascular dementia), 18 healthy subjects, and 18 neurological controls. A follow up investigation (including analysis of a new CSF sample) was performed in all patients after about one year.
MAIN OUTCOME MEASURES—Concentrations of total (both normal tau and PHF-tau) tau in CSF, clinical measures (duration and severity of dementia), and apoE polymorphism.
RESULTS—CSF-tau was markedly increased in Alzheimer's disease, 41/43 (95%) patients had values above the cut off level (mean+2 SD) in controls (306 pg/ml). High CSF-tau concentrations were also found in most patients with vascular dementia, preferentially in patients with vascular dementia without progressive leukoaraiosis on CT, whereas patients with vascular dementia with progressive leukoaraiosis had normal CSF-tau. Concentrations of CSF-tau were stable at one year follow up in both patients with Alzheimer's disease and patients with vascular dementia, and there was no correlation between CSF-tau and either duration or severity of dementia.
CONCLUSIONS—The findings confirm the high sensitivity of CSF-tau for the diagnosis of Alzheimer's disease, but high CSF-tau was also found in vascular dementia, resulting in a lower specificity. However, high CSF-tau is preferentially found in patients with vascular dementia without progressive leukoaraiosis, which may constitute a group with concomitant Alzheimer's disease pathology. High CSF-tau may be present during the whole course of the disease in Alzheimer's disease. Possibly, therefore, the same high CSF-tau concentrations may be present before the onset of clinical dementia. Follow up studies on such patients will tell whether analysis of CSF-tau is useful as a biochemical marker for early Alzheimer's disease.



Full Text

The Full Text of this article is available as a PDF (145.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G., Gore S. M., Gardner M. J., Pocock S. J. Statistical guidelines for contributors to medical journals. Br Med J (Clin Res Ed) 1983 May 7;286(6376):1489–1493. doi: 10.1136/bmj.286.6376.1489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Machida N., Seiki H., Takase S., Clark C. M., Lee V. M. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol. 1995 Oct;38(4):649–652. doi: 10.1002/ana.410380414. [DOI] [PubMed] [Google Scholar]
  3. Arriagada P. V., Growdon J. H., Hedley-Whyte E. T., Hyman B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992 Mar;42(3 Pt 1):631–639. doi: 10.1212/wnl.42.3.631. [DOI] [PubMed] [Google Scholar]
  4. Blennow K., Bogdanovic N., Alafuzoff I., Ekman R., Davidsson P. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm (Vienna) 1996;103(5):603–618. doi: 10.1007/BF01273157. [DOI] [PubMed] [Google Scholar]
  5. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol. 1995 Dec;26(3):231–245. doi: 10.1007/BF02815140. [DOI] [PubMed] [Google Scholar]
  6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–259. doi: 10.1007/BF00308809. [DOI] [PubMed] [Google Scholar]
  7. Coleman P. D., Flood D. G. Neuron numbers and dendritic extent in normal aging and Alzheimer's disease. Neurobiol Aging. 1987 Nov-Dec;8(6):521–545. doi: 10.1016/0197-4580(87)90127-8. [DOI] [PubMed] [Google Scholar]
  8. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993 Aug 13;261(5123):921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]
  9. Folstein M. F., Folstein S. E., McHugh P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6. [DOI] [PubMed] [Google Scholar]
  10. Galasko D., Clark C., Chang L., Miller B., Green R. C., Motter R., Seubert P. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 1997 Mar;48(3):632–635. doi: 10.1212/wnl.48.3.632. [DOI] [PubMed] [Google Scholar]
  11. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 1993 Nov;16(11):460–465. doi: 10.1016/0166-2236(93)90078-z. [DOI] [PubMed] [Google Scholar]
  12. Grundke-Iqbal I., Iqbal K., Tung Y. C., Quinlan M., Wisniewski H. M., Binder L. I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4913–4917. doi: 10.1073/pnas.83.13.4913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Han S. H., Hulette C., Saunders A. M., Einstein G., Pericak-Vance M., Strittmatter W. J., Roses A. D., Schmechel D. E. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol. 1994 Jul;128(1):13–26. doi: 10.1006/exnr.1994.1108. [DOI] [PubMed] [Google Scholar]
  14. Hock C., Golombowski S., Naser W., Müller-Spahn F. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease--correlation with degree of cognitive impairment. Ann Neurol. 1995 Mar;37(3):414–415. doi: 10.1002/ana.410370325. [DOI] [PubMed] [Google Scholar]
  15. Huang D. Y., Weisgraber K. H., Goedert M., Saunders A. M., Roses A. D., Strittmatter W. J. ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation. Neurosci Lett. 1995 Jun 16;192(3):209–212. doi: 10.1016/0304-3940(95)11649-h. [DOI] [PubMed] [Google Scholar]
  16. Ihara Y., Nukina N., Miura R., Ogawara M. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem. 1986 Jun;99(6):1807–1810. doi: 10.1093/oxfordjournals.jbchem.a135662. [DOI] [PubMed] [Google Scholar]
  17. Jellinger K. A. Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol. 1996;91(2):219–220. doi: 10.1007/s004010050418. [DOI] [PubMed] [Google Scholar]
  18. Jensen M., Basun H., Lannfelt L. Increased cerebrospinal fluid tau in patients with Alzheimer's disease. Neurosci Lett. 1995 Feb 17;186(2-3):189–191. doi: 10.1016/0304-3940(95)11297-a. [DOI] [PubMed] [Google Scholar]
  19. Kakulas B. A., Wilton S. D., Fabian V. A., Jones T. M. Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet. 1996 Aug 17;348(9025):483–483. doi: 10.1016/s0140-6736(05)64588-6. [DOI] [PubMed] [Google Scholar]
  20. Kane J. W., Gowland E. A method for the identification of apolipoprotein E isoforms employing chemical precipitation and flat bed isoelectric focusing in agarose. Ann Clin Biochem. 1986 Sep;23(Pt 5):509–513. doi: 10.1177/000456328602300504. [DOI] [PubMed] [Google Scholar]
  21. Kosunen O., Soininen H., Paljärvi L., Heinonen O., Talasniemi S., Riekkinen P. J., Sr Diagnostic accuracy of Alzheimer's disease: a neuropathological study. Acta Neuropathol. 1996;91(2):185–193. doi: 10.1007/s004010050412. [DOI] [PubMed] [Google Scholar]
  22. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  23. Mori H., Hosoda K., Matsubara E., Nakamoto T., Furiya Y., Endoh R., Usami M., Shoji M., Maruyama S., Hirai S. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett. 1995 Feb 17;186(2-3):181–183. doi: 10.1016/0304-3940(95)11291-4. [DOI] [PubMed] [Google Scholar]
  24. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995 Oct;38(4):643–648. doi: 10.1002/ana.410380413. [DOI] [PubMed] [Google Scholar]
  25. Munroe W. A., Southwick P. C., Chang L., Scharre D. W., Echols C. L., Jr, Fu P. C., Whaley J. M., Wolfert R. L. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. Ann Clin Lab Sci. 1995 May-Jun;25(3):207–217. [PubMed] [Google Scholar]
  26. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991 Feb 8;541(1):163–166. doi: 10.1016/0006-8993(91)91092-f. [DOI] [PubMed] [Google Scholar]
  27. Nitsch R. M., Rebeck G. W., Deng M., Richardson U. I., Tennis M., Schenk D. B., Vigo-Pelfrey C., Lieberburg I., Wurtman R. J., Hyman B. T. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol. 1995 Apr;37(4):512–518. doi: 10.1002/ana.410370414. [DOI] [PubMed] [Google Scholar]
  28. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993 Sep 18;342(8873):697–699. doi: 10.1016/0140-6736(93)91705-q. [DOI] [PubMed] [Google Scholar]
  29. Richey P. L., Siedlak S. L., Smith M. A., Perry G. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem Biophys Res Commun. 1995 Mar 17;208(2):657–663. doi: 10.1006/bbrc.1995.1389. [DOI] [PubMed] [Google Scholar]
  30. Riemenschneider M., Buch K., Schmolke M., Kurz A., Guder W. G. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett. 1996 Jul 19;212(3):209–211. doi: 10.1016/0304-3940(96)12810-x. [DOI] [PubMed] [Google Scholar]
  31. Rösler N., Wichart I., Jellinger K. A. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996 Feb;60(2):237–238. doi: 10.1136/jnnp.60.2.237-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Saunders A. M., Hulette O., Welsh-Bohmer K. A., Schmechel D. E., Crain B., Burke J. R., Alberts M. J., Strittmatter W. J., Breitner J. C., Rosenberg C. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet. 1996 Jul 13;348(9020):90–93. doi: 10.1016/s0140-6736(96)01251-2. [DOI] [PubMed] [Google Scholar]
  33. Saunders A. M., Strittmatter W. J., Schmechel D., George-Hyslop P. H., Pericak-Vance M. A., Joo S. H., Rosi B. L., Gusella J. F., Crapper-MacLachlan D. R., Alberts M. J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993 Aug;43(8):1467–1472. doi: 10.1212/wnl.43.8.1467. [DOI] [PubMed] [Google Scholar]
  34. Skoog I., Vanmechelen E., Andreasson L. A., Palmertz B., Davidsson P., Hesse C., Blennow K. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration. 1995 Dec;4(4):433–442. doi: 10.1006/neur.1995.0052. [DOI] [PubMed] [Google Scholar]
  35. Smith A. D., Jobst K. A., Johnston C., Joachim C., Nagy Z. Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet. 1996 Aug 17;348(9025):483–484. doi: 10.1016/s0140-6736(05)64589-8. [DOI] [PubMed] [Google Scholar]
  36. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977–1981. doi: 10.1073/pnas.90.5.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Strittmatter W. J., Weisgraber K. H., Goedert M., Saunders A. M., Huang D., Corder E. H., Dong L. M., Jakes R., Alberts M. J., Gilbert J. R. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Exp Neurol. 1994 Feb;125(2):163–174. doi: 10.1006/exnr.1994.1019. [DOI] [PubMed] [Google Scholar]
  38. Tarvonen-Schröder S., Räihä I., Kurki T., Rajala T., Sourander L. Clinical characteristics of rapidly progressive leuko-araiosis. Acta Neurol Scand. 1995 May;91(5):399–404. doi: 10.1111/j.1600-0404.1995.tb07028.x. [DOI] [PubMed] [Google Scholar]
  39. Tato R. E., Frank A., Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1995 Sep;59(3):280–283. doi: 10.1136/jnnp.59.3.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J. J., Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993 Nov;61(5):1828–1834. doi: 10.1111/j.1471-4159.1993.tb09823.x. [DOI] [PubMed] [Google Scholar]
  41. Vigo-Pelfrey C., Seubert P., Barbour R., Blomquist C., Lee M., Lee D., Coria F., Chang L., Miller B., Lieberburg I. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 1995 Apr;45(4):788–793. doi: 10.1212/wnl.45.4.788. [DOI] [PubMed] [Google Scholar]
  42. Wallin A., Blennow K. Pathogenetic basis of vascular dementia. Alzheimer Dis Assoc Disord. 1991 Summer;5(2):91–102. doi: 10.1097/00002093-199100520-00006. [DOI] [PubMed] [Google Scholar]
  43. Wisniewski T., Frangione B. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett. 1992 Feb 3;135(2):235–238. doi: 10.1016/0304-3940(92)90444-c. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES